目次

1. Introduction to TIGIT Inhibitor

2. Role Of TIGIT Inhibitors By Indications
2.1 TIGIT Inhibitors in Cancer
2.2 TIGIT Inhibitors in HIV
2.3 TIGIT in Autoimmune Disorders

3. Mechanism of Anti TIGIT Antibodies
3.1 Overview
3.2 Clinical Approaches to Target TIGIT

4. Partnerships and Collaborations In The Global Anti TIGIT Antibodies Market

5. Global TIGIT inhibitors Clinical Trials Overview
5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Patient Segment

6. Global Anti TIGIT Antibody Clinical Pipeline By Company, Indication and Phase
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-III

7. FDA Orphan Designation for Tiragolumab

8. Global Anti TIGIT Antibody Market Dynamics

9. 1 Market Drivers

10. 2 Commercialization Challenges

9. Global TIGIT Inhibitor Market Future Outlook

10. Competitive Landscape
10.1 Arcus Biosciences
10.2 Agenus
10.3 Astellas Pharma
10.4 AstraZeneca
10.5 BeiGene
10.6 Bristol Myers Squibb
10.7 Compugen
10.8 Gilead Sciences
10.9 iTeos Therapeutics
10.10 Merck
10.11 Roche
10.12 Seagen
10.13 Shanghai Henlius Biotech

List of Figures & Tables
Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT and PD-1 Blockade
Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
Figure 2-5: TIGIT Associated Autoimmune Disorders
Figure 3-1: TIGIT Inhibitor - Proposed Mechanism of Action
Figure 3-2: TIGIT Inhibitor - Mechanism of Action
Figure 3-3: Binding Efficacy of Monoclonal Antibody
Figure 3-4: Binding Efficacy of Bispecific Antibodies
Figure 3-5: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 5-1: Global - Anti TIGIT Antibodies Clinical Trials by Company, 2023
Figure 5-2: Global - Anti TIGIT Antibodies Clinical Trials by Country, 2023
Figure 5-3: Global - Anti TIGIT Antibodies Clinical Trials By Indication, 2023
Figure 5-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment, 2023
Figure 7-1: Tiragolumab - SKYSCRAPER08 Phase-III Trial Initiation and Completion Year
Figure 8-1: Global - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 8-2: Global - TIGIT Inhibitor Market Drivers
Figure 8-3: Stages of Drug Development